Vimarsana
Biggest News Aggregation in the World

Tech Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tech Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tech Therapeutics Today - Breaking & Trending Today

YolTech Therapeutics to Present and Unveil Major Progress at Biotech Showcase 2024 - Vimarsana News

YolTech Therapeutics to Present and Unveil Major Progress at Biotech Showcase 2024

SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases,

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM - Vimarsana News

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM

/PRNewswire/ -- YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's first in vivo genome editing candidate...

First Patient Dosed In Clinical Trial Of YOLT-201 For The Treatment Of Hereditary ATTR-CM - Vimarsana News

First Patient Dosed In Clinical Trial Of YOLT-201 For The Treatment Of Hereditary ATTR-CM

(MENAFN - PR Newswire) SHANGHAI, Dec. 17, 2023 /PRNewswire/ -- YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's first in vivo genome editing ... ...

Source: wn.com
First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM - Vimarsana News

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM

SHANGHAI, Dec. 17, 2023 /PRNewswire/ — YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company’s first in vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The study by YolTech is a single-arm, open-label, dose-escalation clinical trial (Clinicaltrials.gov: […]

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM - Vimarsana News

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM

YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's first in vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis...